Teniposide
Teniposide is a semisynthetic epipodophyllotoxin derived from podophyllotoxin that inhibits topoisomerase II, causing DNA double-strand breaks and cell cycle arrest at the G2/M phase. It is used in the treatment of childhood acute lymphoblastic leukemia and is active against brain tumors, bladder cancer, and breast cancer. Its antitumor activity is related to stabilization of the cleavable complex between topoisomerase II and DNA, leading to irreversible DNA strand breaks.
分子量
656.7000 g/mol
LogP
1.20
TPSA
189.00 Ų
リピンスキーの五則
不適合
治療領域
作用機序
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
2D構造
Cite this structure
Embed this structure
SMILES
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
InChI
InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
Molecular Formula
C32H32O13S
HBD / HBA
3 / 14
回転可能結合数
6
重原子数
46
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Teniposide is a semisynthetic epipodophyllotoxin derived from podophyllotoxin that inhibits topoisomerase II, causing DNA double-strand breaks and cell cycle arrest at the G2/M phase. It is used in the treatment of childhood acute lymphoblastic leukemia and is active against brain tumors, bladder cancer, and breast cancer. Its antitumor activity is related to stabilization of the cleavable complex between topoisomerase II and DNA, leading to irreversible DNA strand breaks.
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Yes, Teniposide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL452231. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 452548. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="teniposide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/teniposide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/teniposide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/teniposide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="teniposide"></drugfyi-drug>